Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
◎ AmoyDx Essential NGS Panel: Focused on 10 oncogenes approved by FDA for targeted drugs.
◎ Super-ARMS EGFR: Significant improvement on qPCR platform of liquid biopsy EGFR testing.
Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System
AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China